Lyell Immunopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lyell Immunopharma (LYEL).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

1S.Buy

5Buy

1Sell

Consensus RatingBuy# Analysts7Avg. Consensus PT$32Upside to Avg. PT+259.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 11, 2026	Needham	Gil Blum	Maintained	Buy	$44
Aug 6, 2026	Stifel	Stephen Willey	Initiate	Buy	$36
Jul 22, 2026	B. Riley Securities	Yuan Zhi	Initiate	Buy	$44
Jun 15, 2026	Citizens	Reni J. Benjamin	Maintained	Market Outperform	$34
Jun 15, 2026	Needham	Gil Blum	Maintained	Buy	$44
Jun 9, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$45
Jun 8, 2026	Needham	Gil Blum	Maintained	Buy	$44
Jun 3, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$45
May 7, 2026	Needham	Gil Blum	Maintained	Buy	$44
Apr 10, 2026	Needham	Gil Blum	Initiate	Buy	$44
Mar 9, 2026	Citizens	Reni J. Benjamin	Initiate	Market Outperform	$34
Dec 9, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	Upgrade	Neutral→Buy	$20→$45
Nov 24, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Neutral	$10→$20
Sep 26, 2025	LUCID CAPITAL MARKETS	Christopher Liu	Initiate	Buy	$20
Jun 24, 2025	HC Wainwright & Co.	Mitchell Kapoor	PT Raise	Neutral	$1→$10
Apr 16, 2025	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Neutral	$1
Mar 13, 2025	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Neutral	$1
Nov 12, 2024	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Neutral	$1
Oct 30, 2024	B of A Securities	Geoff Meacham	Downgrade	Buy→Underperform	$6→$1
Oct 28, 2024	HC Wainwright & Co.	Mitchell Kapoor	Maintained	Neutral	$1

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

Needham analyst Gil Blum reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $44 price target.

Benzinga Newsdesk

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.

Avi Kapoor

PRO
Stifel Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $36

Stifel analyst Stephen Willey initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $36.

Benzinga Newsdesk

PRO
B. Riley Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44

B. Riley Securities analyst Yuan Zhi initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $44.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price Target

Citizens analyst Reni J. Benjamin reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Market Outperform and maintains $34 price target.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

Needham analyst Gil Blum reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $44 price target.

Benzinga Newsdesk

Lyell Immunopharma Inc

Lyell Immunopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

PRO
Stifel Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $36

PRO
B. Riley Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44

PRO
Citizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price Target

PRO
Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

People Also Watch

People Also Watch

Lyell Immunopharma Inc

Lyell Immunopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRONeedham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

PROStifel Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $36

PROB. Riley Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44

PROCitizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price Target

PRONeedham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

People Also Watch

People Also Watch

PRO
Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

PRO
Stifel Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $36

PRO
B. Riley Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44

PRO
Citizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price Target

PRO
Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target